Soluble HLA class I and HLA-DR plasma levels in patients with anterior uveitis

Tissue Antigens

Volumn 63, Issue 4, 2004, Pages 369-375

  Heiligenhaus, A ^a   Rebmann, V ^b   Neubert, A ^b   Plewa, S ^b   Ferencik, S ^b   Vogeler U ^b   Steuhl, K P ^b   Grosse Wilde, H ^b,c  

^a ST FRANZISKUS HOSPITAL   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Anterior uveitis; Soluble HLA class I; Soluble HLA DR

Indexed keywords

HLA ANTIGEN CLASS 1; HLA B27 ANTIGEN; HLA DR ANTIGEN;

ACUTE DISEASE; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; HLA TYPING; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; IRIDOCYCLITIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY TESTING; HLA-DR ANTIGENS; HUMANS; IRIDOCYCLITIS; UVEITIS, ANTERIOR;

EID: 1642564465     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0001-2815.2004.00201.x     Document Type: Article

References (28)

1. Rothova A, Veenedaal WG, Linssen A, Glasius E, Kijlstra A, de Jong PT et al. Clinical features of acute anterior uveitis. Am J Ophthalmol 1987: 103: 137-45.
2. Linssen A, Meenken C. Outcomes of HLA-B27-positive and HLA-B27-negative acute anterior uveitis. Am J Ophthalmol 1995: 120: 351-61.
3. Jones NP. Fuchs' heterochromic uveitis: an update. Surv Ophthalmol 1993: 37: 253-72.
4. Liesegang TJ. Fuchs Uveitis Syndrome. In: Pepose JS, Holland GN, Wilhelmus KR, eds. Ocular Infection and Immunity. St Louis: Mosby, 1995: 1: 495-506.
5. Thurau SR, Diedrichs-Möhring M, Fricke H, Arbogast S, Wildner G. Molecular mimicry as a therapeutic approach for an autoimmune disease: oral treatment of uveitis-patients with an MHC-peptide crossreactive with autoantigen-first results. Immunol Lett 1997: 57: 193-201.
6. Willbanks GS, Rootman DS, Jay V, Wiggert B, Chamberlain J, Inman RD. Experimental autoimmune uveitis in HLA-B27 transgenic mice. Hum Immunol 1997: 53: 188-94.
7. Bresciani A, Pirozzi G, Spera M, Lombardi ML, Ambrosone L, Migliaresi S et al. Increased level of serum HLA class I antigens in patients with systemic lupus erythematosus. Correlation with disease activity. Tissue Antigens 1998: 52: 44-50.
8. Tsuchiya N, Shiota M, Yamagushi A, Ito K et al. Elevated serum level of soluble HLA class I antigens in patients with systemic lupus erythematosus. Arthritis Rheum 1996: 39: 792-6.
9. Ott M, Seidl C, Westhoff U, Stecker K, Seifried E, Fischer PA et al. Soluble HLA class I and class II antigens in patients with multiple sclerosis. Tissue Antigens 1998: 51: 301-4.
10. Filaci G, Concini P, Brenci S, Gazzole P, Lanza L, Scudeletti M et al. Soluble HLA class I and class II molecule levels in serum and cerebrospinal fluid of multiple sclerosis patients. Hum Immunol 1997: 54: 54-62.
11. Verbrüggen LA, Dumarey N, Van de Velde H, Relomann V, Flament J, Van Weganberge C et al. Soluble HLA-DR antigen levels in serum correlate with rheumatoid arthritis disease activity and the presence of disease-associated epitopes. Tissue Antigens 2000: 56: 436-40.
12. Wolf RE, Adamashvili IM, Gelder FB, Hall VC, Fraser PA, McDonald JC. Soluble HLA-I in rheumatic diseases. Hum Immunol 1998: 59: 644-9.
13. Puppo F, Scudeletti M, Indiveri F, Ferrone S. Serum HLA class I antigens: markers and modulators of an immune response? Immunol Today 1995: 16: 124-7.
14. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992: 39: 225-35.
15. Ferencik S, Grosse-Wilde H. Caucasian German Population. In: Terasaki PI, Gjertson DW, eds. HLA 1997. Los Angeles: UCLA Tissue Typing, 1997, 222-3.
16. Rebmann V, Pfeiffer K, Päßler M, Ferrones S, Maieo S, Weiss E et al. Detection of soluble HLA-G molecules in plasma and amniotic fluid. Tissue Antigens 1999: 53: 14.
17. Ditschkowski M, Kreuzfelder E, Rebmann V, Forchaks S, Majetschak N, Schmid EN et al. HLA-DR expression and soluble HLA-DR levels in septic patients after trauma. Ann Surg 1998: 229: 246.
18. Zavazava N. Soluble HLA class I molecules: biological significance and clinical implications. Mol Med Today 1998: 4: 116-21.
19. Zavazava N, Böttcher H, Mueller-Ruchholtz WM. Soluble MHC class I antigens (sHLA) and anti-HLA antibodies in heart and kidney allograft recipients. Tissue Antigens 1993: 42: 20-6.
20. + cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol 2003: 33: 125-34.
21. Spaggiari GM, Contini P, Dondero A, Carosio R, Puppo F, Indiveri F et al. Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interaction. Blood 2002: 100: 4098-107.
22. + lymphocytes by soluble major histocompatibility complex class II-peptide complexes. J Clin Invest 1994: 93: 1361-9.
23. + T cells by soluble dimeric peptide-MHC class II chimera. Nat Immunol 2002: 3: 383-91.
24. Deschenes J, Char HD, Kaleta S. Activated T lymphocytes in uveitis. Br J Ophthalmol 1988: 72: 83-7.
25. Arocker-Mettinger E, Asenbauer T, Ulbrich S, Grabner G. Serum interleukin 2-receptor levels in uveitis. Curr Eye Res 1990: 9: 25-9.
26. Muhaya M, Calder V, Towler HMA, Shaer B, McLauchlan M, Lightman S. Characterization of T cells and cytokines in the aqueous humour (AH) in patients with Fuchs' heterochromic cyclitis (FHC) and idiopathic anterior uveitis (IAU). Clin Exp Immunol 1998: 111: 123-8.
27. Doxiadis I, Westhoff U, Grosse-Wilde H. Quantification of soluble HLA class I gene products by an enzyme linked immunosorbent assay. Blut 1989: 59: 449-54.
28. Adamashvili IM, McDonald JC, Fraser PA, Milford EL, Pressly TA, Gelder FB. Soluble class I HLA antigens in patients with rheumatoid arthritis and their families. J Rheumatol 1995: 22: 1025-31.